Skip to content

Recognized Experts in ADME / DMPK / DDI by 98% of top pharma & countless others for drug metabolism and drug-drug interaction expertise.

Learn More
1

20% Off* SEKISUI XenoTech Test Systems!

Use up your remaining budget with 20% off* all in-stock standard (not custom prepared) SEKISUI XenoTech test systems, including hepatocytes and media, Kupffer cells, subcellular fractions, tissue...

Webinar – Suicide by Binding: Putting Time-Dependent Inhibition of CYP Enzymes into Perspective

Presenter: Brian Ogilvie, Ph.D., SEKISUI XenoTech Vice President of Scientific Consultingwith special guest for Q&A, Lois Haupt, SEKISUI XenoTech Principal Scientist...

SEKISUI XenoTech Celebrates 25th Anniversary

In 2019, SEKISUI XenoTech celebrated its 25th birthday, and our Japan branch turned 64! Read about our journey from a...

Great reports that are ready for submission to the Agency!

Pharma Senior Vice President of R&D

Every XenoTech employee I had contact with throughout these studies have been a pleasure to work with. The entire process was seamless. I never had...

Regulatory Affairs for Small Pharma

There is a lot of quality, skilled work that has gone into this data set. Compared to organizations that have done this type of work...

ADME Consultant

Great reports that are ready for submission to the Agency!

Pharma Senior Vice President of R&D

Every XenoTech employee I had contact with throughout these studies have been a pleasure...

Regulatory Affairs for Small Pharma

There is a lot of quality, skilled work that has gone into this data...

ADME Consultant

Your drug’s journey…

Your drug’s journey…

057 liver and stomach Created with Sketch.

through the body

through the pipeline

Absorption, Distribution, Metabolism, and Excretion (ADME) properties of a xenobiotic describe its disposition and inform overall fate following administration. SEKISUI XenoTech serves 98% of top pharma and countless others by providing high-quality contracted ADME studies and test systems to precede or support clinical trials.

Drug Metabolism & Pharmacokinetics (DMPK) is a core discipline in drug discovery and development investigating how a drug is broken down and cleared, considering both ADME and DDI characteristics to evaluate and optimize properties of a new drug compound. Our drug metabolism and pharmacokinetics testing and products allows sponsors to understand properties of their compounds and to evaluate risk early in drug development and testing.

Drug-Drug Interaction (DDI) studies allow a drug developer to investigate the potential of a xenobiotic compound to interact with drug-metabolizing enzymes and drug transporters to predict the impact on the pharmacokinetics of the compound or coadministered drugs. Drug metabolism and drug transporter studies provide critical information in evaluating potential for drug-drug interactions and associated risks in preclinical drug development.

In Silico Modeling uses mathematical models to evaluate in vitro data in a way that provides meaningful risk prediction for drug metabolism and drug interaction issues later in development or clinical trials.

In Vitro Studies & Test Systems allow drug developers to use cell-based assays to determine ADME/PK characteristics and DDI potential of their drug compound.

Our In Vivo ADME / PK Studies use radiolabeled drug compound administered to laboratory animals to investigate an investigational compound’s pharmacokinetic propertiesinclusing drug metabolism and DDI risk.

FDA
NIH Leadership 2012
We need better drugs. We need to do better. We need to go faster and be more successful
FDA Commissioner 2017
We need to make sure we’re taking steps to foster innovation and regulating areas of promising new technology in ways that don’t raise the cost of drug development or reduce innovation.
SEKISUI XenoTech facilitates the development of safer drugs with fewer failures and lower costs through our state-of-the-art drug metabolism and DDI testing programs to help drug developers understand as much as possible about their drug's metabolism and pharmacokinetics to properly evaluate related drug safety risks.
Over $2.8 billion is spent on the development of each launched drug
Only 1 in 10,000 potential drug compounds make it all the way through the development pipeline
Over 80% of investigational new drugs fail because of unsatisfactory ADME/Tox

Access ADME™ | Scientific Resources